LYVDELZI

This brand name is authorized in Austria, Estonia, France, Ireland, Italy, Lithuania, Romania, Spain.

Active ingredients

The drug LYVDELZI contains one active pharmaceutical ingredient (API):

1	Seladelpar UNII N1429130KR - SELADELPAR LYSINE
	Seladelpar is a peroxisome proliferator-activated receptor delta (PPARδ) agonist, or delpar. PPARδ is a nuclear receptor expressed in the liver and other tissues. PPARδ activation reduces bile acid synthesis in the liver through Fibroblast Growth Factor 21 (FGF21)-dependent downregulation of CYP7A1, the key enzyme for the synthesis of bile acids from cholesterol and by decreasing cholesterol synthesis and absorption. These actions result in lower bile acid exposure in the liver and reduced circulating bile acid levels.
	Read more about Seladelpar

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LYVDELZI Hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A05AX07		A Alimentary tract and metabolism → A05 Bile and liver therapy → A05A Bile therapy → A05AX Other drugs for bile therapy
Discover more medicines within A05AX07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3113110, 3138375
ES	Centro de información online de medicamentos de la AEMPS	1241898001
FR	Base de données publique des médicaments	63473073
IT	Agenzia del Farmaco	051949016
LT	Valstybinė vaistų kontrolės tarnyba	1102855, 1103719
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W71012001